Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171746
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sánchez Ortega, Isabel | - |
dc.contributor.author | Parody, Rocío | - |
dc.contributor.author | Grupo Español de Trasplante Hematopoyético (GETH) | - |
dc.date.accessioned | 2020-11-04T15:15:00Z | - |
dc.date.available | 2020-11-04T15:15:00Z | - |
dc.date.issued | 2020-03-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/171746 | - |
dc.description.abstract | Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1038/s41409-019-0731-x | - |
dc.relation.ispartof | Bone Marrow Transplantation, 2020, vol. 55, num.3, p. 641-648 | - |
dc.relation.uri | https://doi.org/10.1038/s41409-019-0731-x | - |
dc.rights | cc by (c) Escamilla Gómez, et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Morbiditat | - |
dc.subject.classification | Mortalitat | - |
dc.subject.classification | Cèl·lules mare | - |
dc.subject.other | Morbidity | - |
dc.subject.other | Mortality | - |
dc.subject.other | Stem cells | - |
dc.title | Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2020-11-03T17:12:34Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31700138 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
GomezVE.pdf | 930.05 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License